EU/US plan new approach to developing Gaucher disease drugs
This article was originally published in Scrip
Executive Summary
The European Medicines Agency and the US FDA are developing a "strategic collaborative approach" to the development of pediatric drugs for Gaucher disease that they say should help to generate the high-quality data required for the approval of new products while reducing the economic burden of conducting clinical trials.